DCs as targets for vaccine design

Cytotherapy

Volumn 6, Issue 2, 2004, Pages 88-98

  Belz, Gabrielle T ^a   Smith, C M ^a   Bharadwaj, M ^b   Rice, A M ^c   Jackson, D C ^b  

^a WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c MATER MEDICAL RESEARCH INSTITUTE   (Australia)

Author keywords

Antigen presentation; Dendritic cells; Immunity; Tolerance; Virus

Indexed keywords

B7 ANTIGEN; CD11B ANTIGEN; CD4 ANTIGEN; CD40 ANTIGEN; CD45 ANTIGEN; CD8 ANTIGEN; CYTOKINE; EPITOPE; FC RECEPTOR; GAMMA INTERFERON; GLYCOPROTEIN P 15095; IMMUNOLOGICAL ADJUVANT; INTERLEUKIN 12; INTERLEUKIN 4; LIPOPEPTIDE; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; MANNOSE RECEPTOR; SYNTHETIC PEPTIDE; TOLL LIKE RECEPTOR; VACCINE;

ADOPTIVE IMMUNOTHERAPY; ANTIBODY PRODUCTION; ANTIGEN PRESENTATION; ANTIGEN PRESENTING CELL; CELL ACTIVATION; CELL FUNCTION; CELL MATURATION; CELL TYPE; DENDRITIC CELL; DRUG DESIGN; ENDOCYTOSIS; GRAFT REJECTION; GRAFT VERSUS HOST REACTION; HERPES SIMPLEX; HOST PATHOGEN INTERACTION; HUMAN; IMMUNE RESPONSE; IMMUNOLOGICAL TOLERANCE; IN VIVO STUDY; LEISHMANIASIS; MAJOR HISTOCOMPATIBILITY COMPLEX; NONHUMAN; PHAGOCYTOSIS; PINOCYTOSIS; REVIEW; SENSITIZATION; T LYMPHOCYTE;

EID: 2642518999     PISSN: 14653249     EISSN: None     Source Type: Journal    
DOI: 10.1080/14653240410005276     Document Type: Review

References (68)

1. Shortman K, Caux C. Dendritic cell development: multiple pathways to nature's adjuvants. Stem Cells 1997;15:409-19.
2. Jonas N, O'Neill H. Manipulation of dendritic cells for immunotherapy of tumours. Today Life Sci 2000;Nov/Dec:42-8.
3. Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature 1998;392:245-52.
4. Banchereau J, Briere F, Caux C et al. Immunobiology of dendritic cells. Annu Rev Immunol 2000;18:767-811.
5. Steinman R. The dendritic cell system and its role in immunogenicity. Annu Rev Immunol 1991;9:271-96.
6. + T cells by exogenous cell-associated antigens. Immunity 2002;17:211-20.
7. Fanger NA, Wardwell K, Shen L et al. Type I (CD64) and type II (CD32) Fc gamma receptor-mediated phagocytosis by human blood dendritic cells. J Immunol 1996;157:541-8.
8. Esposito-Farese ME, Sautes C, de la Salle H et al. Membrane and soluble Fc gamma RII/III modulate the antigen-presenting capacity of murine dendritic epidermal Langerhans cells for IgG-complexed antigens. J Immunol 1995;155:1725-36.
9. Reis e Sousa C, Stahl PD, Austyn JM. Phagocytosis of antigens by Langerhans cells in vitro. J Exp Med 1993;178:509-19.
10. Castellino F, Boucher PE, Eichelberg K et al. Receptor-mediated uptake of antigen/heat shock protein complexes results in major histocompatibility complex Class I antigen presentation via two distinct processing pathways. J Exp Med 2000;191:1957- 64.
11. Arnold-Schild D, Hanau D, Spehner D et al. Cutting edge: receptor-mediated endocytosis of heat shock proteins by professional antigen-presenting cells. J Immunol 1999;162:3757-60.
12. Platt N, da Silva RP, Gordon S. Class A scavenger receptors and the phagocytosis of apoptotic cells. Biochem Soc Trans 1998;26:639-44.
13. Delneste Y, Magistrelli G, Gauchat J et al. Involvement of L0X-1 in dendritic cell-mediated antigen cross-presentation. Immunity 2002;17:353-62.
14. Valladeau J, Ravel O, Dezutter-Dambuyant C et al. Langerin, a novel C-type lectin specific to Langerhans cells, is an endocytic receptor that induces the formation of Birbeck granules. Immunity 2000;12:71-81.
15. Sallusto F, Cella M, Danieli C, Lanzavecchia A. Dendritic cells use macropinocytosis and the mannose receptor to concentrate macromolecules in the major histocompatibility complex Class II compartment: downregulation by cytokines and bacterial products. J Exp Med 1995;182:389-400.
16. Jiang W, Swiggard WJ, Heufler C et al. The receptor DEC-205 expressed by dendritic cells and thymic epithelial cells is involved in antigen processing. Nature, 1995;375:151-5.
17. Guermonprez P, Valladeau J, Zitvogel L et al. Antigen presentation and T cell stimulation by dendritic cells. Annu Rev Immunol 2002;20:621-67.
18. Geijtenbeek TB, Kwon DS, Torensma R et al. DC-SIGN, a dendritic cell-specific HIV-1-binding protein that enhances trans-infection of T cells. Cell 2000;100:587-97.
19. Geissmann F, Launay P, Pasquier B et al. A subset of human dendritic cells expresses IgA Fc receptor (CD89), which mediates internalization and activation upon cross-linking by IgA complexes. J Immunol 2001;166:346-52.
20. - dendritic cells in vivo. J Exp Med 2002;196:817-27.
21. Jurgens M, Wollenberg A, Hanau D et al. Activation of human epidermal Langerhans cells by engagement of the high affinity receptor for IgE, Fc epsilon R1. J Immunol 1995;155:5184-9.
22. Engering A, Cella M, Fluitsma D et al. Mannose receptor mediated antigen uptake and presentation in human dendritic cells. Adv Exp Med Biol 1997;417:183-7.
23. Edwards AD, Diebold SS, Slack EM et al. Toll-like receptor expression in murine DC subsets: lack of TLR7 expression by CD8 alpha+ DC correlates with unresponsiveness to imidazo-quinolines. Eur J Immunol 2003;33:827-33.
24. Takeuchi O, Akira S. Genetic approaches to the study of Toll-like receptor function. Microbes Infect 2002;4:887-95.
25. Norbury CC, Hewlett LJ, Prescott AR et al. Class I MHC presentation of exogenous soluble antigen via macro-pinocytosis in bone marrow macrophages. Immunity 1995;3:783-91.
26. Sallusto F, Mackay CR, Lanzavecchia A. The role of chemokine receptors in primary, effector, and memory immune responses. Annu Rev Immunol 2000;18:593-620.
27. Inaba K, Metlay JP, Crowley MT, Steinman R. Dendritic cells pulsed with protein antigens in vitro can prime antigen specific MHC-restricted T cells in situ. J Exp Med 1990;172:631-40.
28. + T cells and process soluble antigen. J Immunol 1995;155:5427-35.
29. Austyn JM. Death, destruction, danger and dendritic cells. Nat Med 1999;5:1232-3.
30. Jackson DC, Purcell AW, Fitzmaurice CJ et al. The central role of played by peptides in the immune response and the design of peptide based vaccines against infectious diseases and cancer. Current Drug Targets 2002;3:175-96.
31. Purcell AW, Zeng W, Mifsud NA et al. Dissecting the role of peptides in the immune response: theory, practice and the application to vaccine design. J Pept Sci 2003;9:255-81.
32. Heath WR, Carbone FR. Cross-presentation in viral immunity and self-tolerance. Nat Rev Immunol 2001;1:126-34.
33. + pro-B cells can give rise to dendritic cells in vitro. J Immunol 1998;161:5795-9.
34. Izon DK, Rudd W, DeMuth WS et al. A common pathway for dendritic cell and early B cell development. J Immunol 2001;167:1387-92.
35. Ardavi C, Wu L, Li CL, Shortman K. Thymic dendritic cells and T cells develop simultaneously in the thymus from a common precursor population. Nature 1993;362:761-3.
36. Asselin-Paturel C, Boonstra A, Dalod M et al. Mouse type I IFN-producing cells are immature APCs with plasmacytoid morphology. Nat Immunol 2001;2:1144-50.
37. + cells in mouse lymph nodes and spleen display characteristics of plasmacytoid dendritic cells. J Exp Med 2001; 194:1171-8.
38. + dendritic cells endowed with type 1 interferon production capacity and tolerogenic potential. Blood 2002;100:383-90.
39. Arpinati M, Green C, Heimfeld S et al. Granulocyte colony stimulating factor mobilizes T helper 2 inducing dendritic cells. Blood 2000;95:2484-90.
40. Sato K, Yamashita N, Baba M, Matsuyama T. Modified myeloid dendritic cells act as regulatory dendritic cells to induce anergic and regulatory T cells. Blood 2003;101:3581-9.
41. Sato K, Yamashita N, Yamashita N et al. Regulatory dendritic cells protect mice from murine acute graft-versus-host disease and leukemia relapse. Immunity 2003;18:367-79.
42. Hart DN. Dendritic cells: unique leukocyte populations which control the primary immune response. Blood 1997;90:3245-87.
43. Osugi Y, Vuckovic S, Hart DN. Myeloid blood CD11c(+) dendritic cells and monocyte-derived dendritic cells differ in their ability to stimulate T lymphocytes. Blood 2002;100:2858-66.
44. MacDonald KP, Munster DJ, Clark GJ et al. Characterization of human blood dendritic cell subsets. Blood 2002;100:4512-20.
45. + dendritic cells are preferentially involved in CTL priming after footpad infection with Herpes simplex virus-1. J Immunol 2003;170:4437-40.
46. + dendritic cells. J Immunol 2001;166:5327-30.
47. + T cell polarization in mice is modulated by strain-specific major histocompatibility complex-independent differences within dendritic cells. J Exp Med 2003;198:201-9.
48. Von Stebut E, Ehrchen JM, Belkaid Y et al. Interleukin 1 {alpha} promotes Th 1 differentiation and inhibits disease progression in Leishmania major-susceptible BALB/c mice. J Exp Med 2003;198:191-9.
49. Sigal LJ, Crotty S, Andino R, Rock KL. Cytotoxic T-cell immunity to virus-infected non-haematopoietic cells requires presentation of exogenous antigen. Nature 1999;398:77-80.
50. Liu YJ. Dendritic cell subsets and lineages, and their functions in innate and adaptive immunity. Cell 2001;106:259-62.
51. Hochrein H, Shortman K, Vremec D et al. Differential production of IL-12, IFN-alpha, and IFN-gamma by mouse dendritic cell subsets. J Immunol 2001;166:5448-55.
52. Diebold SS, Montoya M, Unger H et al. Viral infection switches non-plasmacytoid dendritic cells into high interferon producers. Nature 2003;424:324-8.
53. Agrawal A, Lingappa J, Leppla SH et al. Impairment of dendritic cells and adaptive immunity by anthrax lethal toxin. Nature 2003;424:329-34.
54. Belz GT, Behrens GM, Smith CM et al. The CD8alpha(+) dendritic cell is responsible for inducing peripheral self-tolerance to tissue-associated antigens. J Exp Med 2002;196:1099-104.
55. Hugues S, Mougneau E, Ferlin W et al. Tolerance to islet antigens and prevention from diabetes induced by limited apoptosis of pancreatic beta cells. Immunity 2002;16:169-81.
56. Bonifaz L, Bonnyay D, Mahnke K et al. Efficient targeting of protein antigen to the dendritic cell receptor DEC-205 in the steady state leads to antigen presentation on major histocompatability complex Class I products and peripheral CD8+ T cell tolerance. J Exp Med 2002;196:1627-38.
57. Banchereau J, Paczesny S, Blanco P et al. Dendritic cells: controllers of the immune system and a new promise for immunotherapy. Ann NY Acad Sci 2003;987:180-7.
58. Blanco P, Palucka AK, Gill M et al. Induction of dendritic cell differentiation by IFN-alpha in systemic lupus erythematosus. Science 2001;294:1540-3.
59. Mahnke K, Qian Y, Knop J, Enk AH. Dendritic cells, engineered to secrete a T-cell receptor mimic peptide, induce antigen-specific immunosuppression in vivo. Nat Biotechnol 2003;21:903-8.
60. Steinman RM, Pope M. Exploiting dendritic cells to improve vaccine efficacy. J Clin Invest 2002;109:1519-26.
61. Fitzmaurice CJ, Brown LE, McInerney TL, Jackson DC. The assembly and immunological properties of non-linear synthetic immunogens containing T-cell and B-cell determinants. Vaccine 1996;14:553-60.
62. Fitzmaurice CJ, Brown LE, Kronin V, Jackson DC. The geometry of synthetic peptide-based immunogens affects the efficiency of T cell stimulation by professional antigen-presenting cells. Int Immunol 2000;12:527-35.
63. BenMohamed L, Wechsler SL, Nesburn AB. Lipopeptide vaccines-yesterday, today, and tomorrow. Lancet Infect Dis 2002;2:425-31.
64. Zeng W, Jackson DC, Murray J et al. Totally synthetic lipid-containing polyoxime peptide constructs are potent immunogens. Vaccine 2000;18:1031-9.
65. Zeng W, Ghosh S, Lau YF et al. Highly immunogenic and totally synthetic lipopeptides as self-adjuvanting immunocontraceptive vaccines. J Immunol 2002;169:4905-12.
66. Deliyannis G, Jackson DC, Ede NJ et al. Induction of long-term memory CD8( + ) T cells for recall of viral clearing responses against influenza virus. J Virol 2002;76:4212-21.
67. Chua BY, Healy A, Cameron PU et al. Maturation of dendritic cells with lipopeptides that represent vaccine candidates for hepatitis C virus. Immunol Cell Biol 2003;81:67-72.
68. Takeuchi O, Sato S, Horiuchi T et al. Cutting edge: role of Toll-like receptor 1 in mediating immune response to microbial lipoproteins. J Immunol 2002;169:10-4.